Does the FDA recommend HRT for menopause

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, the agency does recommend hormone therapy for menopause, but only for specific purposes: treating moderate to severe hot flashes, preventing bone loss, and treating genitourinary syndrome of menopause. The FDA recommends using the lowest effective dose for the shortest amount of time that still provides meaningful symptom relief.

Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

What the FDA Officially Says

According to FDA.gov, menopausal hormone therapy (estrogen with or without progesterone) is approved for three situations:

• Hot flashes and night sweats: According to FDA.gov, systemic estrogen is considered the most well-studied treatment when symptoms are moderate to severe.
• Bones: According to FDA.gov, estrogen may help prevent bone loss after menopause and is viewed as an option when other bone medications are not suitable.
• Vaginal and urinary symptoms: According to FDA.gov, local estrogen (creams, rings, tablets) is approved for dryness, pain with intercourse, and urinary discomfort.

According to FDA.gov, hormone therapy is not recommended for preventing heart disease, improving memory, or for age-related wellness purposes. Research reviewed by the FDA has not shown benefit in those areas, and FDA boxed warnings note risks including stroke, blood clots, and pulmonary embolism.

What "Lowest Dose for the Shortest Time" Really Means

• Lowest dose: According to FDA.gov, treatment should begin at a low dose, increasing only if symptoms remain significant. This approach reduces unnecessary hormonal exposure.
• Shortest time: This does not mean ending therapy abruptly. According to FDA.gov, it means continuing only as long as symptoms meaningfully interfere with quality of life.
• Personalized decisions: According to FDA.gov, duration is not fixed; patients may remain on therapy longer when the benefits clearly outweigh the risks, as determined by a qualified prescriber.

Why the FDA Takes This Approach

According to FDA-approved prescribing information, estrogen carries risks including blood clots and, for women with a uterus, a higher risk of uterine cancer when estrogen is used without progesterone. The FDA's guidance is designed to allow meaningful symptom relief while minimizing unnecessary exposure to those risks. All treatment decisions should be made with a qualified prescriber who may review individual risk factors.

According to FDA.gov, hormone therapy for menopause is supported when symptoms are significant, and the agency encourages individualized, carefully monitored use under the care of a qualified prescriber.